

Audit Committee Meeting
June 22, 2016; 8:00-9:30 a.m.

I. Attendance. Participating in all or part of the meeting by telephone were the following individuals.

Directors:

John Sobeck, M.D, Chairman - Market Medical Executive, Cigna
Dennis Kirkpatrick - CFO, Welfare & Pension Administrative Service, Inc.
Jason Farber, Esq. - Davis Wright Tremaine, LLP

KidsVax®:

Julia Walter, Deputy Executive Director
Ashley Kittrell, Executive Assistant
Claire Roberge, Controller
Norm Roberge, Accountant
Peter Smith, Financial Analyst
Fred Potter, Executive Director

Others:

Allen Gilbert, CPA - CliftonLarsonAllen
Jan Hicks-Thomson - Department of Health

II. Summary of Actions Taken and/or Recommended

A. Actions Taken (votes adopted)

1. To approve the Washington Vaccine Association (WVA) FYE 2016/17 budget subject to additional changes as directed by Committee members.
2. To pay an additional \$1 million dollars on the line of credit (LOC) before 6/30/2016.

III. Meeting Minutes

At 8:00 a.m., Chairman John Sobeck called the meeting to order and asked all participants to introduce themselves. A quorum having been established, the meeting proceeded.

Financial Update

Peter Smith began the update by informing the Committee that \$1 million dollars had recently been paid on the line of credit (LOC) and suggested paying an additional \$1 million dollars before the end of the fiscal year on June 30. Doing so ensures that the WVA meets the LOC's step-down requirement from \$15 million dollars to \$10 million dollars by July 31, 2016. Mr. Smith also noted

1 that there will be an increase in cash flows once the 2016 assessment grid goes into effect on July
2 1. Dennis Kirkpatrick asked if the cash requirements would still be met if an additional \$1 million
3 dollars is paid on the LOC. Mr. Smith replied that there would be sufficient funds given the current
4 cash balance of \$9.7 million dollars. The Committee agreed that additional funds should be
5 allocated toward paying down the LOC.

6 7 **Collections Report**

8 Norm Roberge discussed the collections report and recent re-captioning of the Accounts
9 Receivable (AR) section of the financial report. KidsVax® (KV) staff and Allen Gilbert recently
10 met to discuss renaming and the amount listed. As discussed during the last Committee meeting
11 in March, the amount is an estimate of what the WVA expects to collect based on vaccine purchase
12 and has been renamed as “Assessments Receivable.” Mr. Roberge, with Mr. Gilbert, agreed upon
13 a \$15 million dollars write down. Mr. Roberge asked if there were any questions regarding this
14 change. There being none, Chairman Soback asked Ms. Walter to proceed with KV updates.

15 16 KV Updates

17 18 **Assessment Grid**

19 Ms. Walter informed the Committee that the 2016 assessment grid is scheduled to take effect on
20 July 1, pursuant to the Board’s decision at the April meeting to adjust the assessment grid to reflect
21 a weighted average of 130% of the CDC contract prices and not to exceed the CDC market survey
22 price on any vaccine. The WVA has updated the grid on the website and sent email notifications
23 of the effective date and where to download the grid. The Department of Health (DOH) has also
24 sent a blast fax to all provider offices informing them of the change and directing questions to the
25 WVA.

26 27 **WVA 2016/17 Budget**

28 Fred Potter then directed the Committee to the proposed WVA 2016/17 Budget in the packet. He
29 reviewed each item, explaining that minimal changes had been made concerning TRICARE and
30 budgeted legal fees. There are two components to TRICARE: the special project, which has a
31 \$20,000 monthly cap and the monthly \$10,000 expenditure for the continued engagement of
32 government affairs firm, Crowell & Moring (C&M). The majority of work surrounding TRICARE
33 is expected to be completed by January 2017. Mr. Kirkpatrick asked if it might be prudent to look
34 into paying C&M hourly as opposed to a monthly fee. Ms. Walter explained it is to the WVA’s
35 benefit that the lead partner does not charge an hourly rate and provided insight into C&M’s work,
36 which includes multiple meetings with legislative assistants, conducting door to door meetings in
37 order to garner support from key representatives, and managing the current contract with the public
38 relations firm.

39
40 Continuing with the budget, Mr. Potter initially recommended reducing the legal fees from last
41 year’s budget to \$25,000 dollars. However, in light of potential enterprise threats, he recommended

1 allocating \$35,000 dollars. Dr. Sobeck then asked for questions or comments. Jason Farber
2 informed the Committee that he could not approve the budget without more time to review. Mr.
3 Potter stated that any changes to the budget could be recommended by Committee members before
4 presenting it for final approval by the Board of Directors.

5
6 Audit Update

7
8 Gilbert Allen from CliftonLarsonAllen (CLA) gave an update on the upcoming WVA Audit. He
9 confirmed that he met with KV to review the AR section and approves of the write down
10 methodology in order to reflect the true amount in the WVA balance sheet. The audit work is
11 scheduled for the week of July 11 and CLA will have draft audit documents available for the next
12 Audit Committee meeting on September 13.

13
14 Other Matters from Committee Members

15
16 There were no other matters to discuss.

17
18 Closing

19
20 There being no further business, the meeting adjourned at 8:57 a.m.



What: Audit Committee Meeting
 Date & Time: Wednesday, June 22nd; 8:00-9:30 a.m.
 Location: Teleconference
 Conference Line: 605-562-3180; Conference ID: 103063718#

Notice: Meeting may be recorded for the benefit of the secretary. The WVA intends to delete the recording after the minutes of the meeting are approved.

Approx. Time	Topic/[Anticipated Action]	Presented by:
8:00-8:05 a.m.	1. Welcome & Introductions	J. Sobeck
8:05-8:20 a.m. *	2. Financial Update	P. Smith
* a.	LOC Pay-down	
* b.	Collections Report	N. Roberge
8:20-8:35 a.m.	3. KidsVax Updates	J. Walter/F. Potter
* a.	2016 Assessment Grid	
* b.	WVA 2016/17 Budget	
8:35-8:50 a.m.	4. Audit Update	A. Gilbert
8:50-8:55 a.m.	5. Other Matters from Committee Members	Any
8:55-9:00 a.m.	6. Closing	J. Sobeck

*Indicates Agenda Item Attached

Washington Vaccine Association
Thirteen (13) Months of Key Financial Information
Prepared by Norm Roberge - KidsVax, LLC

	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	12 Months
	2015	2015	2015	2015	2015	2015	2015	2015	2016	2016	2016	2016	2016	Average
	(000)	(000)	(000)	(000)	(000)	(000)	(000)	(000)	(000)	(000)	(000)	(000)	(000)	(000)
Cash Balance	3,249	2,112	2,549	1,296	2,587	1,776	4,445	6,558	5,805	4,765	7,040	6,937	6,139	4,334
Investments	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Prepaid Vaccines	5,779	6,340	5,108	7,142	9,515	5,300	4,245	4,198	5,432	4,814	4,498	5,357	4,998	5,579
Line of Credit Outstanding	14,000	15,000	15,000	15,000	15,000	15,000	15,000	14,000	14,000	12,000	12,000	12,000	11,000	13,750
Assessments Collected	3,972	4,095	5,638	6,059	8,212	7,306	7,032	7,428	4,834	5,893	6,880	5,359	5,346	6,174
Payments to DOH (non flu)	5,779	6,340	5,108	7,142	5,658	4,828	4,244	4,198	5,432	4,814	4,498	5,357	5,041	5,222
Payments to DOH - Flu	-	-	-	-	3,857	472	-	-	-	-	-	-	-	n/a
Line of Credit Interest	(35)	(36)	(38)	(39)	(38)	(39)	(38)	(38)	(38)	(33)	(34)	(33)	(32)	(36)

- No unusual activity seen in claims data.
- \$1 million was paid on the LOC in May totaling \$2 million paid in 2016.

Prepared 6/10/2016

**Washington Vaccine Association
Statement of Financial Position
As of May 31, 2016**

A**ASSETS**

Current assets		
1	Cash and cash equivalents	\$ 6,139,333.25
2	Investments	9,705.42
3	Assessment receivable	20,934,831.00
4	Prepaid Vaccine	4,997,681.19
5	Prepaid Administrative Services	-
6	Total current assets	32,081,550.86
7	Total assets	\$ 32,081,550.86

LIABILITIES AND NET ASSETS

Current liabilities		
8	Accounts payable	\$ 34,835.94
9	Key Bank - Line of Credit	11,000,000.00
10	Payable to Washington Department of Health	-
11	Other accruals	-
12	Total current liabilities	11,034,835.94
Net assets		
13	Excess Assessments - Vaccines	32,418,466.44
14	Excess Assesments - Administrative Activities	(11,371,751.52)
15	Total net assets	21,046,714.92
16	Total liabilities and net assets	\$ 32,081,550.86

**Washington Vaccine Association
Statement of Activities and Changes in Net Assets**

		Month Ending May 31, 2016			For 11 Months Ending May 31, 2016		
		Administrative Activities	Vaccine Activities	Total	Administrative Activities	Vaccine Activities	Total
Revenues:							
1	Assessments	\$ 1,251,869.26	\$ 5,250,797.00	\$ 6,502,666.26	\$ 17,351,220.89	\$ 61,276,034.00	\$ 78,627,254.89
2	Less: Vaccine expense	-	(5,401,631.47)	(5,401,631.47)	-	(61,994,441.57)	(61,994,441.57)
3	Net Assessment margins	1,251,869.26	(150,834.47)	1,101,034.79	17,351,220.89	(718,407.57)	16,632,813.32
4	Investment income	-	-	-	-	-	-
5	Other income	-	-	-	-	-	-
6	Net revenues	1,251,869.26	(150,834.47)	1,101,034.79	17,351,220.89	(718,407.57)	16,632,813.32
Expenses:							
7	Administrative services - fixed contract	34,481.92	-	34,481.92	417,281.13	-	417,281.13
8	Adm services - variable compensation	-	-	-	-	-	-
9	Administrative services - Tricare	28,110.11	-	28,110.11	221,391.51	-	221,391.51
10	Legal fees	977.50	-	977.50	27,628.01	-	27,628.01
11	Audit	-	-	-	9,500.00	-	9,500.00
12	Annual report / special communications	-	-	-	10,058.75	-	10,058.75
Special projects:							
13	DOH vaccine order system	-	-	-	-	-	-
14	Denied claims recovery	2,500.00	-	2,500.00	27,576.96	-	27,576.96
15	All other special projects	382.00	-	382.00	91,360.29	-	91,360.29
16	Insurance	-	-	-	43,518.94	-	43,518.94
17	Bank fees	3,815.14	-	3,815.14	56,234.59	-	56,234.59
18	Investment advisor / manager	-	-	-	-	-	-
19	Other administration expenses	-	-	-	-	-	-
20	Total administrative expenses	70,266.67	-	70,266.67	904,550.18	-	904,550.18
21	Line of credit - financing costs	32,335.94	-	32,335.94	398,972.22	-	398,972.22
22	Total expenses	102,602.61	-	102,602.61	1,303,522.40	-	1,303,522.40
23	Increase (decrease) in net assets	\$ 1,149,266.65	\$ (150,834.47)	\$ 998,432.18	\$ 16,047,698.49	\$ (718,407.57)	\$ 15,329,290.92
24	Unrestricted net assets, beginning of year				(27,419,450.01)	33,136,874.01	5,717,424.00
25	Unrestricted net assets, end of year				\$ (11,371,751.52)	\$ 32,418,466.44	\$ 21,046,714.92

Unaudited - For Management Purposes Only
Prepared by KidsVax, LLC

Washington Vaccine Association
Statement of Cash Flows
For the Periods Ending

2016-06-22 WVA Audit Committee 2.4

	A Inception Through 3/31/2016	B Month 4/30/2016	C Month 5/31/2016	D Inception Through 5/31/2016
1 Cash balance - beginning of period	\$ -	\$ 7,050,138.15	\$ 6,947,163.17	\$ -
Inflows:				
2 Principal prepayments	7,800,001.00	-	-	7,800,001.00
3 Vaccine collections	289,035,595.23	5,359,159.28	5,346,077.26	299,740,831.77
4 Interest income	53,408.37	-	-	53,408.37
5 Investment income/ (loss)	149,787.97	-	-	149,787.97
6 Key Bank - LOC advances	12,000,000.00	-	(1,000,000.00)	11,000,000.00
7 Total inflows	309,038,792.57	5,359,159.28	4,346,077.26	318,744,029.11
Outflows:				
8 Principal repayments	(7,799,908.85)	-	-	(7,799,908.85)
Program				
9 Vaccine remittance State of WA	(288,897,734.46)	(5,357,382.78)	(5,041,929.88)	(299,297,047.12)
10 Vaccine Selection Development	(79,950.00)	-	-	(79,950.00)
11 Public information	(132,002.06)	-	-	(132,002.06)
12 Total program disbursements	(289,109,686.52)	(5,357,382.78)	(5,041,929.88)	(299,508,999.18)
Administration				
13 Administrative services	(2,510,045.99)	(63,496.59)	(62,974.03)	(2,636,516.61)
14 Project management fees	(419,878.90)	-	-	(419,878.90)
15 Denied claims recovery	(72,133.44)	(2,500.00)	(2,500.00)	(77,133.44)
16 Design and advertising	(31,031.38)	-	-	(31,031.38)
17 Claims system development	(26,000.00)	-	-	(26,000.00)
18 Legal fees	(267,572.36)	-	(977.50)	(268,549.86)
19 Audit fees	(74,655.00)	-	-	(74,655.00)
20 Website and information technology	(113,993.32)	-	-	(113,993.32)
21 Travel	(1,829.68)	-	-	(1,829.68)
22 Total administration	(3,517,140.07)	(65,996.59)	(66,451.53)	(3,649,588.19)
Office				
23 Bank Fees	(446,050.67)	(5,269.66)	(3,815.14)	(455,135.47)
24 Office supplies	958.92	-	-	958.92
25 Postage and shipping	(1,438.36)	-	-	(1,438.36)
26 Printing	(4,819.61)	-	-	(4,819.61)
27 Office Rent	(51,313.90)	-	-	(51,313.90)
28 Telephone	(2,514.23)	-	-	(2,514.23)
29 Total office	(505,177.85)	(5,269.66)	(3,815.14)	(514,262.65)
Other				
30 Insurance	(156,503.07)	-	-	(156,503.07)
31 Interest Line of Credit	(899,877.06)	(33,485.23)	(32,005.21)	(965,367.50)
32 Board meetings	(361.00)	-	-	(361.00)
33 Total Other	(1,056,741.13)	(33,485.23)	(32,005.21)	(1,122,231.57)
34 Total outflows	(301,988,654.42)	(5,462,134.26)	(5,144,201.76)	(312,594,990.44)
35 Cash balance - end of period	\$ 7,050,138.15	\$ 6,947,163.17	\$ 6,149,038.67	\$ 6,149,038.67

Note: Cash balance includes amounts in Key Bank and Morgan Stanley

Washington Vaccine Association

Line of Credit Paydown Alternatives

(Balance of \$12 Million as of 4/8/2016)

Date	Aggressive	< Cash Balance	Medium	< Cash Balance	Conservative	< Cash Balance
April	\$ 1,000,000	\$ 6,038,794	\$ -	\$ 7,038,794	\$ -	\$ 7,038,794
May	1,000,000	6,779,292	500,000	8,276,584	-	8,776,584
June***	1,500,000	5,293,342	1,000,000	7,286,571	-	8,785,217
July*	1,000,000	5,171,421	1,000,000	7,159,233	-	9,653,817
August	1,000,000	1,022,060	1,000,000	3,004,455	2,000,000	4,492,268
September***	-	4,122,209	1,000,000	5,099,188	1,000,000	6,582,938
October	2,000,000	4,619,652	1,500,000	6,093,923	1,000,000	8,073,610
November	2,000,000	4,502,935	2,000,000	5,973,144	1,000,000	8,947,415
December**	2,500,000	3,298,502	4,000,000	3,264,648	7,000,000	3,230,794
Total	\$ 12,000,000		\$ 12,000,000		\$ 12,000,000	
 Total Interest	 \$ 148,200		 \$ 180,700		 \$ 213,200	
 Incremental Cost	 \$ -		 \$ 32,500		 \$ 65,000	

Notes:

- * The line of credit must be paid down to \$10 Million by August 1, 2016.
- ** The line of credit must be paid off by January 1, 2017.
- *** WVA Cash Balance must be at least \$4 Million at the end of each calendar quarter.

Washington Vaccine Association
June 16, 2016

To: Julia
From: Norm

Below are 2 examples of how we allocate collections received based on claim dates of service.

Schedule 1 is meant to illustrate the collection pattern that existed prior to the allocation changes made in the spring of 2015. As you can see we were collecting approximately 24% in the month in which we paid DOH for the vaccines.

Schedule 2 is meant to illustrate the collection pattern that existed after the change in allocation in the spring of 2015. The payers were processing claims in the same manner as before the allocation changes this produced a lower percentage of collections per month as measured against the anticipated collections. This lower percentage collection rate is what spurred the WVA to question as to why we were not receiving anticipated monies. The task force was formed and DOH was able to identify the problem and correct.

WVA is left with the uncollected anticipated collections and will be writing down the amount left on the books to an amount that closer resembles Schedule 1

SCHEDULE 1												
Prior to change in allocations by CDC/DOH												
	January	%	February	%	March	%	April	%	May	%	June	6 Month Totals
Anticipated Future Collections in the month WVA pays DOH	\$ 1,000,000	100.00%	\$ 1,000,000	100.00%	\$ 1,000,000	100.00%	\$ 1,000,000	100.00%	\$ 1,000,000	100.00%	\$ 1,000,000	\$ 6,000,000
Collections WVA receives are analysed and distributed to : the months that they pertain to based on the date of service on the claim												
In January we collect for January and months prior	\$ (240,000)	-24.00%	\$ -		\$ -		\$ -		\$ -		\$ -	\$ (240,000)
In February we collect for February and months prior	\$ (570,000)	-57.00%	\$ (240,000)	-24.00%								\$ (810,000)
In March we collect for March and months prior	\$ (100,000)	-10.00%	\$ (570,000)	-57.00%	\$ (240,000)	-24.00%						\$ (910,000)
In April we collect for April and months prior	\$ (46,000)	-4.60%	\$ (100,000)	-10.00%	\$ (570,000)	-57.00%	\$ (240,000)	-24.00%				\$ (956,000)
In May we collect for May and months prior	\$ (10,000)	-1.00%	\$ (46,000)	-4.60%	\$ (100,000)	-10.00%	\$ (570,000)	-57.00%	\$ (240,000)	-24.00%		\$ (966,000)
In June we collect for June and months prior	\$ (8,000)	-0.80%	\$ (10,000)	-1.00%	\$ (46,000)	-4.60%	\$ (100,000)	-10.00%	\$ (570,000)	-57.00%	\$ (240,000)	\$ (974,000)
Total collected	\$ (974,000)	-97.40%	\$ (966,000)	-96.60%	\$ (956,000)	-95.60%	\$ (910,000)	-91.00%	\$ (810,000)	-81.00%	\$ (240,000)	\$ (4,856,000)
Uncollected	\$ 26,000	2.60%	\$ 34,000	3.40%	\$ 44,000	4.40%	\$ 90,000	9.00%	\$ 190,000	19.00%	\$ 760,000	\$ 1,144,000

SCHEDULE 2													
After change in CDC/DOH allocations													
When the CDC / DOH changed the allocation between VFC and non-VFC children WVA paid more to DOH and WVA calculation of anticipated future collections increased accordingly. A problem became apparent when the payers were paying on actual claims and the claims were similar to the period prior to the change in allocations													
Anticipated Future Collections in the month WVA pays DOH	\$ 1,600,000	100.00%	\$ 1,600,000	100.00%	\$ 1,600,000	100.00%	\$ 1,600,000	100.00%	\$ 1,600,000	100.00%	\$ 1,600,000	100.00%	\$ 9,600,000
Collections WVA receives are analysed and distrituted to : the months that they pertain to based on the date of service on the claim													
In January we collect for January and months prior	\$ (240,000)	-15.00%	\$ -		\$ -		\$ -		\$ -		\$ -		\$ (240,000)
In February we collect for February and months prior	\$ (570,000)	-35.63%	\$ (240,000)	-15.00%									\$ (810,000)
In March we collect for March and months prior	\$ (100,000)	-6.25%	\$ (570,000)	-35.63%	\$ (240,000)	-15.00%							\$ (910,000)
In April we collect for April and months prior	\$ (46,000)	-2.88%	\$ (100,000)	-6.25%	\$ (570,000)	-35.63%	\$ (240,000)	-15.00%					\$ (956,000)
In May we collect for May and months prior	\$ (10,000)	-0.63%	\$ (46,000)	-2.88%	\$ (100,000)	-6.25%	\$ (570,000)	-35.63%	\$ (240,000)	-15.00%			\$ (966,000)
In june we collect for June and months prior	\$ (8,000)	-0.50%	\$ (10,000)	-0.63%	\$ (46,000)	-2.88%	\$ (100,000)	-6.25%	\$ (570,000)	-35.63%	\$ (240,000)	-15.00%	\$ (974,000)
	\$ (974,000)	-60.88%	\$ (966,000)	-60.38%	\$ (956,000)	-59.75%	\$ (910,000)	-56.88%	\$ (810,000)	-50.63%	\$ (240,000)	-15.00%	\$ (4,856,000)
	\$ 626,000	39.13%	\$ 634,000	39.63%	\$ 644,000	40.25%	\$ 690,000	43.13%	\$ 790,000	49.38%	\$ 1,360,000	85.00%	\$ 4,744,000

Washington Vaccine Association Assessment Grid

2016-06-22 WVA Audit Committee 3.a.1

FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1st, 2016.

Please note that this WVA Assessment Grid, **effective July 1, 2016**, replaces the grid last updated on July 1, 2015. The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands will be determined by the manufacturer and all brands of flu vaccine may not be part of the childhood vaccine program. For a complete listing of all vaccines available through the state Childhood Vaccine Program, please visit the DOH web site:

www.doh.wa.gov/cfh/immunize/vaccine/vaccine-supply.htm.

CPT Code	CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2015	CDC Market Survey	Assessment Amount per dose as of 7/1/2016	Percent change	Notes
90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, Serogroup B, 2 dose schedule, for intramuscular use	Bexsero	\$159.84	\$160.75	\$160.74	0.6%	
90621	Meningococcal recombinant lipoprotein vaccine, Serogroup B, 2 or 3 dose schedule, for intramuscular use	Trumenba	\$124.48	\$115.75	\$115.74	-7.0%	
90633	Hepatitis A vaccine, pediatric/adolescent dosage (2-dose schedule), for intramuscular use (Code Price is per dose = 0.5 mL)	Havrix	\$22.11	\$30.14	\$24.98	13.0%	Weighted average used in determining rate
		Vaqta					
90636	Hepatitis A & Hepatitis B vaccine (HepA-HepB) adult dosage, for intramuscular use (Code Price is per 1 mL).	Twinrix	\$69.91	\$95.23	\$77.35	10.6%	Age 18 only, no doses expected
90644	Meningococcal conjugate vaccine, serogroups C & Y and Hemophilus influenza B vaccine (Hb-MenCY), 4 dose schedule, when administered to high risk children 2 - 15 months of age, for intramuscular use	MenHibrix	\$13.13	\$24.71	\$14.72	12.1%	
90647	Hemophilus influenza b vaccine (Hib), PRP-OMP conjugate (3-dose schedule), for intramuscular use (Code price is per dose = 0.5 mL)	PedvaxHIB	\$16.04	\$23.65	\$17.44	8.7%	
90648	Hemophilus influenza b vaccine (Hib), PRP-T conjugate (4-dose schedule), for intramuscular use (Code price is per dose = 0.5 mL)	Act HIB	\$12.29	\$28.82	\$13.35	8.6%	
90649	Human Papilloma Virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Gardasil	\$154.09	n/a	n/a	n/a	Removed from CDC list, no doses expected
90650	Human Papilloma virus (HPV) vaccine, types 16, 18, bivalent, 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Cervarix	\$140.36	n/a	n/a	n/a	Removed from CDC list, no doses expected

CPT Code	CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2015	CDC Market Survey	Assessment Amount per dose as of 7/1/2016	Percent change	Notes
90651	Human Papilloma Virus (HPV) 9 (nine) valent vaccine, types 6, 11, 16, 18, 31, 33, 45, 52, 58, 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Gardasil 9	\$174.54	\$177.70	\$177.69	1.8%	125,645 doses forecast
90670	Pneumococcal conjugate vaccine, 13 valent, for intramuscular use (Prenar 13 was FDA approved on 2/24/10)	Prenar 13	\$151.98	\$159.58	\$159.57	5.0%	135,997 doses forecast
90680	Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use (Code Price is per dose = 2 mL)	RotaTeq	\$83.15	\$78.18	\$78.17	-6.0%	
90681	Rotavirus vaccine, human, attenuated, 2 dose schedule, live, for oral use (Code Price is per 1 mL = 1 dose)	Rotarix	\$110.55	\$109.73	\$109.72	-0.8%	
90696	Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated (DTaP-IPV), when administered to children 4 years through 6 years of age, for intramuscular use (Code Price is per one dose = 0.5 mL)	Kinrix	\$50.05	\$48.60	\$48.59	-2.9%	Quadracel was removed from CDC list, no doses forecast
		Quadracel					
90698	Diphtheria, tetanus toxoids, acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated (DTaP - Hib - IPV), for intramuscular use (Code Price is per one dose = 0.5 mL)	Pentacel	\$70.69	\$87.48	\$79.53	12.5%	
90700	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use (Code price is per 0.5 mL dose)	Daptacel	\$20.85	\$28.41	\$23.38	12.1%	Weighted average used in determining rate
		Infanrix					
90707	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use (Code Price is per 0.5 mL)	MMRII	\$25.87	\$62.79	\$28.10	8.6%	
90710	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use (Code Price is per one dose = 0.5 mL)	ProQuad	\$141.71	\$180.05	\$159.66	12.7%	
90713	Poliovirus vaccine, inactivated, (IPV), for subcutaneous or intramuscular use (Code Price is per 0.5 mL dose)	IPOL	\$16.35	\$30.17	\$17.78	8.7%	
90714	Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, when administered to individuals 7 years or older, for intramuscular use (Code Price is per 0.5 mL)	Tenivac	\$24.47	\$29.73	\$25.60	4.6%	
90715	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use (Code Price is per dose = 0.5 mL)	BOOSTRIX	\$40.63	\$43.42	\$43.41	6.8%	
		ADACEL					
90716	Varicella virus vaccine, live, for subcutaneous use (Code Price is per 0.5 mL)	Varivax	\$108.90	\$107.67	\$107.66	-1.1%	
90723	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B and poliovirus vaccine, inactivated (DtaP-HepB-IPV), for intramuscular use (Code price is per 0.5 mL)	Pediarix	\$70.02	\$72.73	\$72.72	3.9%	

CPT Code	CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2015	CDC Market Survey	Assessment Amount per dose as of 7/1/2016	Percent change	Notes
90732	Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use (Code price is per 0.5 mL dose)	Pneumovax 23	\$57.17	\$78.90	\$64.84	13.4%	
90734	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 (tetraivalent), for intramuscular use (Code Price is per dose = 0.5 mL)	Menactra Menveo	\$109.93	\$119.75	\$119.09	8.3%	Weighted average used in determining rate
90743	Hepatitis B vaccine, adolescent dosage (2-dose schedule), for intramuscular use (Code price is per dose) (Recombivax HB 10mcg = one dose)	Recombivax HB	\$14.40	\$23.95	\$17.19	19.4%	Only 4,191 doses forecast
90744	Hepatitis B vaccine, pediatric/adolescent dosage (3-dose schedule), for intramuscular use (Code price is per dose)	ENGRIX B Recombivax HB	\$14.40	\$22.40	\$16.21	12.6%	No RecombivaxHB forecast for this CPT code

Pediatric Influenza Vaccine Assessments

90672	Influenza virus vaccine, quadrivalent, live, for intranasal use (Code price is per dose = 0.2 mL)	Flumist	\$24.54	\$23.70	\$23.69	-3.5%	
90685	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 mL dose)	Fluzone Pediatric Preservative Free (PF)	\$23.32	\$23.17	\$23.16	-0.7%	
90686	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to individuals 3 years and older, for intramuscular use (Code Price is per 0.5 mL dose)	Preservative Free (PF) Preservative Free (PF) Preservative Free (PF) Preservative Free (PF)	\$18.27	\$16.82	\$16.81	-8.0%	
90687	Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use	Fluzone	\$17.10	\$18.48	\$18.47	8.0%	
90688	Influenza virus vaccine, quadrivalent, split virus, when administered to children 3 years of age and older, for intramuscular use	Fluzone FluLaval	\$17.10	\$16.62	\$16.61	-2.9%	

Washington Vaccine Association Assessment Grid

2016-06-22 WVA Audit Committee 3.a.4

DRAFT - FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1st, 2015.

Updated on 4/30/2015

Please note that this WVA Assessment Grid, **effective July 1, 2015**, replaces the grid last updated on December 1, 2013. The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands will be determined by the manufacturer and all brands of flu vaccine may not be part of the childhood vaccine program. For a complete listing of all vaccines available through the state Childhood Vaccine Program, please visit the DOH web site: www.doh.wa.gov/cfh/Immunize/vaccine/vaccine-supply.htm.

CPT Code	CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2015
90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, Serogroup B, 2 dose schedule, for intramuscular use	Bexsero	\$159.84
90621	Meningococcal recombinant lipoprotein vaccine, Serogroup B, 2 or 3 dose schedule, for intramuscular use	Trumenba	\$124.48
90633	Hepatitis A vaccine, pediatric/adolescent dosage (2-dose schedule), for intramuscular use (Code Price is per dose = 0.5 mL)	Havrix	\$22.11
		Vaqta	
90636	Hepatitis A & Hepatitis B vaccine (HepA-HepB) adult dosage, for intramuscular use (Code Price is per 1 mL).	Twinrix	\$69.91
90644	Meningococcal conjugate vaccine, serogroups C & Y and Hemophilus influenza B vaccine (Hb-MenCY), 4 dose schedule, when administered to high risk children 2 - 15 months of age, for intramuscular use	MenHibrix	\$13.13
90647	Hemophilus influenza b vaccine (Hib), PRP-OMP conjugate (3-dose schedule), for intramuscular use (Code price is per dose = 0.5 mL)	PedvaxHIB	\$16.04
90648	Hemophilus influenza b vaccine (Hib), PRP-T conjugate (4-dose schedule), for intramuscular use (Code price is per dose = 0.5 mL)	Act HIB	\$12.29
90649	Human Papilloma Virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Gardasil	\$154.09
90650	Human Papilloma virus (HPV) vaccine, types 16, 18, bivalent, 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Cervarix	\$140.36
90651	Human Papilloma Virus (HPV) 9 (nine) valent vaccine, types 6, 11, 16, 18, 31, 33, 45, 52, 58, 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Gardasil 9	\$174.54
90670	Pneumococcal conjugate vaccine, 13 valent, for intramuscular use (Prevnar 13 was FDA approved on 2/24/10)	Prevnar 13	\$151.98
90680	Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use (Code Price is per dose = 2 mL)	RotaTeq	\$83.15

CPT Code	CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2015
90681	Rotavirus vaccine, human, attenuated, 2 dose schedule, live, for oral use (Code Price is per 1 mL = 1 dose)	Rotarix	\$110.55
90696	Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated (DTaP-IPV), when administered to children 4 years through 6 years of age, for intramuscular use (Code Price is per one dose = 0.5 mL)	Kinrix	\$50.05
		Quadracel	
90698	Diphtheria, tetanus toxoids, acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated (DTaP - Hib - IPV), for intramuscular use (Code Price is per one dose = 0.5 mL)	Pentacel	\$70.69
90700	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use (Code price is per 0.5 mL dose)	Daptacel	\$20.85
		Infanrix	
90707	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use (Code Price is per 0.5 mL)	MMRII	\$25.87
90710	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use (Code Price is per one dose = 0.5 mL)	ProQuad	\$141.71
90713	Poliovirus vaccine, inactivated, (IPV), for subcutaneous or intramuscular use (Code Price is per 0.5 mL dose)	IPOL	\$16.35
90714	Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, when administered to individuals 7 years or older, for intramuscular use (Code Price is per 0.5 mL)	Tenivac	\$24.47
90715	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use (Code Price is per dose = 0.5 mL)	BOOSTRIX	\$40.63
		ADACEL	
90716	Varicella virus vaccine, live, for subcutaneous use (Code Price is per 0.5 mL)	Varivax	\$108.90
90723	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B and poliovirus vaccine, inactivated (DtaP-HepB-IPV), for intramuscular use (Code price is per 0.5 mL)	Pediarix	\$70.02
90732	Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use (Code price is per 0.5 mL dose)	Pneumovax 23	\$57.17
90734	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 (tetravalent), for intramuscular use (Code Price is per dose = 0.5 mL)	Menactra	\$109.93
		Menveo	
90743	Hepatitis B vaccine, adolescent dosage (2-dose schedule), for intramuscular use (Code price is per dose) (Recombivax HB 10mcg = one dose)	Recombivax HB	\$14.40

2016-06-22 WVA Audit Committee

CPT Code	CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2015
90744	Hepatitis B vaccine, pediatric/adolescent dosage (3-dose schedule), for intramuscular use (Code price is per dose)	ENGRIX B	\$14.40
		Recombivax HB	
Pediatric Influenza Vaccine Assessments			
90672	Influenza virus vaccine, quadrivalent, live, for intranasal use (Code price is per dose = 0.2 mL)	Flumist	\$24.54
90685	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 mL dose)	Fluzone Pediatric Preservative Free (PF)	\$23.32
90686	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to individuals 3 years and older, for intramuscular use (Code Price is per 0.5 mL dose)	Fluzone Preservative Free (PF)	\$18.27
		Fluarix Preservative Free (PF)	
		Fluvirin Preservative Free (PF)	
		Afluria Preservative Free (PF)	
90687	Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use	Fluzone	\$17.10
90688	Influenza virus vaccine, quadrivalent, split virus, when administered to children 3 years of age and older, for intramuscular use	Fluzone	\$17.10
		FluLaval	

**Washington Vaccine Association
Statement of Activities and Changes in Net Assets**

	A		B	A	B
	For 11 Months Ending May 31, 2016			for 12 months ending	
	Administrative	Vaccine	Actuals for 11 months	30-Jun-16	
	Activities	Activities	ending May 2016	(Projected)	
Revenues:					
1 Assessments	\$ 17,351,220.89	\$ 61,276,034.00	\$ 78,627,254.89	\$ 83,627,254.89	
2 Less: Vaccine Expense	-	(61,994,441.57)	(61,994,441.57)	(66,992,122.76)	
3 Net Assessment Margins	17,351,220.89	(718,407.57)	\$ 16,632,813.32	\$ 18,144,887.26	
4 Investment Income	-	-	-	-	
5 Other Income	-	-	-	-	
6 Net Revenue	17,351,220.89	(718,407.57)	16,632,813.32	18,144,887.26	
				-	
Expenses:					
7 Administrative services - Fixed Contract	379,301.08	-	379,301.08	413,781.00	
8 Adm services -variable compensation	37,980.05	-	37,980.05	37,980.05	
9 Admin services - TRICARE	161,391.51	-	161,391.51	185,735.51	
10 Admin services - TRICARE legislative initiative	60,000.00	-	60,000.00	80,000.00	
11 Legal fees	27,628.01	-	27,628.01	30,139.65	
12 Audit	9,500.00	-	9,500.00	9,500.00	
13 Annual Report / Special Communications	10,058.75	-	10,058.75	10,973.18	
Special Projects:			-	-	
14 Denied Claims Recovery	27,576.96	-	27,576.96	30,083.96	
15 All Other	91,360.29	-	91,360.29	91,360.29	
16 Insurance	43,518.94	-	43,518.94	43,518.94	
17 Bank Fees	56,234.59	-	56,234.59	61,346.83	
18 Other	-	-	-	-	
19 Total administrative Expenses	904,550.18	-	904,550.18	986,782.01	
				-	
20 Line of Credit - Financing Costs	398,972.22	-	398,972.22	431,308.16	
				-	
21 Total expenses	1,303,522.40	-	1,303,522.40	1,422,024.44	
22 Increase (decrease) in net assets	\$ 16,047,698.49	\$ (718,407.57)	\$ 15,329,290.92	\$ 16,722,862.82	
23 Unrestricted net assets, beginning of year	(27,419,450.01)	33,136,874.01	5,717,424.00	5,717,424.00	
24 Unrestricted net assets, end of year	\$ (11,371,751.52)	\$ 32,418,466.44	\$ 21,046,714.92	\$ 22,440,286.82	

Budget worksheet

C	D
2015/16 Expense Budget	2016/17 Expense Budget
Approved June 2015	Recommended June 2016
413,783	428,265
41,378 ^a	42,827 ^a
120,000	180,000
0	60,000
50,000 ^b	25,000 ^b
17,500	11,000 ^c
35,000 ^d	35,000 ^d
30,000	33,600 ^e
10,000	10,000
25,000	45,000
100,000	75,000
842,661	945,692

TRICARE special project added in 2014

Notes:

^a This is full contractual target. The board retains full discretion as to actual final amount.

Some nominal legal expenses should be anticipated as a baseline. Additionally, the Treasurer has requested Anne Redmann to attend every meeting. Finally, although the TRICARE claim is expected to be handled by outside counsel under a contingent-fee arrangement, WVA itself should anticipate some related legal/audit expenses.

^c

^d Desautel Hege communications contract -- estimated costs.

^e AMCC claims recovery services for 12 months.

⁷ Suggested WVA data security audit, internal & external (see ED report)